This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.89% per year. These returns cover a period from January 1, 1988 through March 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Johnson & Johnson (JNJ) and Cisco Systems, Inc. (CSCO), as well as a micro-cap NeurAxis, Inc. (NRXS).
AMZNNegative Net Change JNJPositive Net Change CSCOPositive Net Change EFXPositive Net Change AONPositive Net Change CDNSNegative Net Change NRXSPositive Net Change
computers medical pharmaceuticals retail
Buy Hims (HIMS) or Novo Nordisk (NVO) Stock After Partnership Announcement?
by Shaun Pruitt
Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.
NVOPositive Net Change HIMSNegative Net Change LLYPositive Net Change
investing large-cap medical pharmaceuticals
Humana's Q1 Earnings Beat Estimates on CenterWell Segment Strength
by Zacks Equity Research
HUM's first-quarter results reflect higher primary care revenues and a well-performing Medicare stand-alone PDP business, partly offset by elevated operating costs.
HUMPositive Net Change HCAPositive Net Change CNCPositive Net Change EHCPositive Net Change
earnings medical
Tenet Beats Q1 Earnings on Strong Ambulatory Unit, Ups '25 EPS View
by Zacks Equity Research
THC's first-quarter results benefit on the back of higher net revenue per case and the expansion of service lines within the Ambulatory Care unit. It currently expects 2025 adjusted EPS within $11.99-$13.12.
THCPositive Net Change HCAPositive Net Change CNCPositive Net Change ELVPositive Net Change
earnings medical
Hims & Hers vs. Teladoc: Which Telehealth Stock Is the Better Buy Now?
by Debanjana Dey
Both HIMS and TDOC are technology-intensive healthcare companies that leverage their strengths in the digital health space to enhance their platforms. Which one is a better investment? Let's see.
TDOCNegative Net Change HIMSNegative Net Change
medical medical-devices
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance
by Zacks Equity Research
GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs.
SNYPositive Net Change GSKPositive Net Change JNJPositive Net Change VIRPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
GE HealthCare Q1 Earnings & Sales Beat Estimates, Net Margin Rises
by Zacks Equity Research
GEHC's first-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves on better pricing.
MASINegative Net Change FMSPositive Net Change AHCOPositive Net Change GEHCPositive Net Change
earnings medical medical-devices
Do Options Traders Know Something About Alkermes Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Alkermes stock based on the movements in the options market lately.
ALKSNo Net Change
medical
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
by Harshit Gupta
The medical device industry is growing fast in 2025, but faces supply and trade issues. Major companies to report earnings on May 1, stay tuned!
BDXPositive Net Change BAXPositive Net Change SYKPositive Net Change CAHPositive Net Change DXCMPositive Net Change
medical medical-devices
Will Declining Medical Customers Affect Cigna's Q1 Earnings?
by Zacks Equity Research
CI's first-quarter results are likely to have benefited from growing pharmacy revenues and fees.
CIPositive Net Change CORPositive Net Change BNTCNegative Net Change TARSPositive Net Change
earnings insurance medical
Best Growth Stocks to Buy for April 30th
by Zacks Equity Research
LMB, UHS and BGC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 30, 2025.
BGCNegative Net Change UHSPositive Net Change LMBPositive Net Change
business-services finance medical
Best Value Stocks to Buy for April 30th
by Zacks Equity Research
SKM, TAK and PHIN made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 30, 2025.
SKMPositive Net Change TAKPositive Net Change PHINNegative Net Change
auto-tires-trucks computers medical
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
by Moumi Mondal
MedTech bigwigs, such as CVS, HOLX and IDXX, are set to post their quarterly results tomorrow. Can they deliver on expectations?
HOLXNegative Net Change CVSPositive Net Change IDXXNegative Net Change
earnings medical medical-devices
Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?
by Ekta Bagri
GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the oncology business is under pressure. We advise investors to remain on the sidelines at current levels.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Boost Your Portfolio With These 5 Low Price-to-Book Stocks
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, MD, PFE, STNE and SAN are some such stocks.
PFEPositive Net Change MDPositive Net Change CNCPositive Net Change SANNegative Net Change STNENegative Net Change
finance medical
Strong Segmental Performance to Drive Stryker's Q1 Earnings?
by Zacks Equity Research
SYK's first-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
SYKPositive Net Change APositive Net Change EDAPPositive Net Change GMEDNegative Net Change
medical medical-devices
Best Income Stocks to Buy for April 30th
by Zacks Equity Research
SKM, TAK and SONY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 30, 2025.
SKMPositive Net Change TAKPositive Net Change SONYPositive Net Change
communications consumer-discretionary dividend-yield medical
TECH Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and a rise in biotech customers' ordering trends in the fiscal third quarter.
MASINegative Net Change TECHNegative Net Change VEEVPositive Net Change HIMSNegative Net Change
earnings medical
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
JAZZPositive Net Change AMRXNegative Net Change
biotechs cancer cannabis earnings-preview marijuana medical
New Strong Buy Stocks for April 30th
by Zacks Equity Research
DB, SPOT, SONY, CIVB and TAK have been added to the Zacks Rank #1 (Strong Buy) List on April 30, 2025.
DBNegative Net Change CIVBNegative Net Change SPOTPositive Net Change TAKPositive Net Change SONYPositive Net Change
computers consumer-discretionary finance medical
Is Healthcare Losing the Status of Safe Haven? ETFs in Focus
by Sanghamitra Saha
Healthcare stocks face new risks under Trump, despite their usual defensive reputation.
PFEPositive Net Change SPYNegative Net Change XLVPositive Net Change XHSNegative Net Change IHEPositive Net Change MEDPPositive Net Change IDNAPositive Net Change
etfs immuno-therapy medical
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?
by Shaun Pruitt
Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.
PFEPositive Net Change JNJPositive Net Change NVOPositive Net Change LLYPositive Net Change ABBVPositive Net Change
coronavirus dividend-investing dividends earnings investing medical pharmaceuticals vaccines
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down
by Zacks Equity Research
REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. Stock down.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Community Health Q1 Earnings Top on Rising Patient Volumes, Stock Up 8%
by Zacks Equity Research
CYH continues to witness growth in same-store admissions in the first quarter. Net loss per share is expected between 55 cents and breakeven in 2025.
CYHPositive Net Change ANIPPositive Net Change AVAHNo Net Change ONCPositive Net Change
earnings finance medical
ECL Stock Up in Pre-Market Following Q1 Earnings Meet Estimates
by Zacks Equity Research
Ecolab's robust performance across the majority of its segments drives its first-quarter organic sales despite business challenges.
ECLPositive Net Change MASINegative Net Change FMSPositive Net Change GKOSPositive Net Change
earnings medical medical-devices